Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
According to a recent study from The University of Toledo, even at levels that are currently recognized, early exposure to the common class of insecticides known as pyrethroids may increase the risk of autism and other developmental disorders.
Read Full NewsUreteroscopy and histopathology should be considered as routine preoperative assessments
Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state
1.
FDA Approves Camizestrant for ESR1-Mutated Breast Cancer
2.
CAR-T Trial Raises Prospect of Preventing Myeloma in High-Risk Group
3.
Spicy Chip Death Lawsuit; Gen X and Cancer; Extreme U.S. Temperatures
4.
Lung Cancer Screening Rates in Eligible Adults Remain Low, Uneven
5.
Study finds 1 in 12 patients labeled as having 'benign' results actually had high-risk prostate cancer
1.
Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control
2.
Understanding SVR Normal Range: A Guide to Achieving Optimal Health
3.
Understanding Purpura Fulminans: Causes, Symptoms and Treatment Options
4.
Tumor Bed Regeneration and Tissue Reconstruction: Scientific Review and Clinical Insights
5.
Tumor Dormancy and Cancer Recurrence: Mechanisms, Clinical Implications, and Future Directions
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
3.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge